Related Experiment Video
Updated: Dec 23, 2025
07:51
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
12.4K
Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction
Jaekyu Shin1, Nancy K Hills2, Patrick R Finley1
1Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
Pharmacotherapy
|April 29, 2020
Summary
Initiating certain antidepressants with beta-blockers increases hospitalization risk due to CYP2D6 inhibition. Potent inhibitors like fluoxetine pose a higher risk for hemodynamic events in patients on beta-blockers.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Interactions
Background:
- Beta-blockers and antidepressants are widely prescribed in the US.
- Some antidepressants inhibit cytochrome P450 2D6 (CYP2D6) liver enzymes.
- This inhibition can elevate beta-blocker levels, risking adverse events like hypotension and falls.
Purpose of the Study:
- To investigate if starting antidepressants increases hemodynamic adverse events in patients on beta-blockers.
- To assess the risk of hospital admissions or ED visits for excessive beta-blockade.
Main Methods:
- Survival analysis of adult California Medicaid beneficiaries (2004-2012).
- Included patients on beta-blockers that are CYP2D6 substrates (e.g., metoprolol, propranolol, carvedilol).
- Analyzed concurrent antidepressant use and its association with hospitalizations/ED visits.
Main Results:
- 21,292 patients met criteria; 4.3% had hospital/ED visits within 30 days.
- Antidepressants with moderate-to-strong CYP2D6 inhibition (e.g., fluoxetine, paroxetine) increased risk (HR 1.53, p=0.04).
- Advanced age, male sex, higher beta-blocker doses, and minority ethnicity were linked to increased morbidity.
Conclusions:
- Starting specific antidepressants with beta-blockers elevates the risk of serious medical events.
- The risk is higher with potent CYP2D6-inhibiting antidepressants, suggesting a metabolic drug interaction.
- Clinical awareness of these interactions is crucial for patient safety.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
01:25Pharmacokinetics: Drug–Drug Interactions
265
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
265
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
01:23Antidepressant Drugs: MAOIs and Other Agents
694
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
694
01:22Heart Failure Drugs: β-Blockers
674
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
674
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.2K